RxSight, Inc. (NASDAQ:RXST) Q3 2023 Earnings Call Transcript

Ron Kurtz: Well, I would look back to what we’ve done over the past several years, where we’ve continued to drive innovation of the technology. We’ve mentioned before that we’ve had over 30 PMA supplements approved by the FDA since our initial FDA approval. And those have driven — they can be considered incremental advances, but cumulatively, they have a significant impact on both outcomes as well as the usability of the technology. And so this is the way that we penetrate the market, both on the practice side as well as on the patient side. Continuing to raise the bar of our technology, and we’ll continue to do that for many years to come.

Steven Lichtman: Great. Thanks, Ron.

Operator: I’m showing no further questions at this time. I would now like to turn it back to Ron for closing remarks.

Ron Kurtz: Well, thank you all for your time and attention today. As always, we appreciate your interest in RxSight, and we look forward to updating you on our progress in future quarters. Goodbye.

Operator: This does conclude the program. You may now disconnect.